Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China
Close monitoring, particularly in patients receiving chemotherapy-incorporating regimens, is crucial during the first 30 days post-tislelizumab treatment to manage SADR risks. Proactive measures should be implemented if SADR occur.
Authors
- Meng Guang-yi
- Dajian Chen
- Li Yang (ORCID: https://orcid.org/0000-0002-2528-5087)
- Qianxi Chen (ORCID: https://orcid.org/0009-0009-1161-7579)
- Shaohuan Lu
Institutions
- Shandong Institute of Food and Drug Inspection (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1371/journal.pone.0329464
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00